Quantitative benefit risk assessment (qBRA) is a process that follows a quantitative framework to compare the benefit-risk profile of a medical product and other option(s), using elicited benefit-risk tradeoff preference as an input, and producing outputs in metrics that are relevant to benefit-risk assessment of the medical product.
This task force will provide practical guidance for the design, conduct and reporting of quantitative benefit-risk analyses (qBRA). This includes:
- defining the formal qBRA process
- providing emerging good practices on the implementation of each step of the qBRA
- describing how the results should be interpreted in a unified qBRA framework
- describing how the qBRA process and results should be reported for scientific and regulatory audiences.
Regulatory agencies are now actively encouraging and using qBRA for marketing authorization of drugs and devices. European Medicines Agency (EMA) is currently involved in the public-private Innovative Medicines Initiative (IMI) research consortium. The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle Project (PREFER) under IMI is an important area in EMA’s regulatory strategy to 2025. In the US, FDA has committed under PDUFA VI to enhance their use of BRA in regulatory decision making across medical products, including drugs, biologics and medical devices. Despite all the recent regulatory interest in qBRA, there is little existing guidance to help researchers conduct a scientifically rigorous qBRA.
Martin Ho, MS, BS, PhD
Tommi Tervonen, PhD
Bennett Levitan, PhD, MD
Kevin Marsh, PhD, BA, MA
Katherine Payne, MSc, PhD
Francesco Pignatti, PhD
Praveen Thokala, PhD, MASc
Jorien Veldwijk, MSc, BSc
Rick Vreman, MSc, PharmD
Member of Patient Council of the Michael J. Fox Foundation for Parkinson’s Research
New York, NY, USA